CRVS
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
Corvus Pharmaceuticals, Inc. (CRVS) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | D (1.2) | D+ (1.8) | C- (2.0) | C+ (2.6) | C- (2.0) |
| 2026-11-04 | C+ (2.5) | D (1.2) | C- (1.9) | C- (2.0) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | C+ (2.5) | D (1.2) | C- (1.9) | C (2.3) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | C+ (2.5) | D (1.2) | C- (1.9) | C (2.2) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | C+ (2.5) | D (1.2) | C- (1.9) | C (2.3) | C+ (2.6) | C- (2.1) |